NCT05218304 is a NA clinical trial of Blood sample in Diabetes, sponsored by Agence Sanitaire et Sociale de Nouvelle Calédonie.

Who is sponsoring NCT05218304?

NCT05218304 is sponsored by Agence Sanitaire et Sociale de Nouvelle Calédonie.

What drugs are being tested in NCT05218304?

Interventions in NCT05218304: Blood sample.

What condition does NCT05218304 study?

NCT05218304 studies Diabetes, Hypercholesterolemia, Renal Failure, Dengue Fever, Zika, Chikungunya, Ross River, Malaria, SARS-CoV Infection, Chronic Disease.

Is NCT05218304 still recruiting?

NCT05218304 is currently suspended. Last updated 1 February 2022.

Last reviewed 2022-02-01 · How we verify

NCT05218304

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Baromètre Santé Adulte 2021-2022

Suspended NA Last updated 1 February 2022

What this trial tests

NA trial testing Blood sample in Diabetes in 5,471 participants. Suspended.

Timeline

26 July 2021

Primary endpoint
30 April 2022

30 May 2022

Quick facts

Lead sponsor	Agence Sanitaire et Sociale de Nouvelle Calédonie
Phase	NA
Status	Suspended
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	other
Enrollment	5,471
Start date	26 July 2021
Primary completion	30 April 2022
Estimated completion	30 May 2022
Sites	1 location across New Caledonia

Drugs / interventions tested

Blood sample — full drug profile →

Conditions studied

Diabetes — all drugs for Diabetes →
Hypercholesterolemia — all drugs for Hypercholesterolemia →
Renal Failure — all drugs for Renal Failure →
Dengue Fever — all drugs for Dengue Fever →

Sponsor

Agence Sanitaire et Sociale de Nouvelle Calédonie

Who can join

Adults 18 to 64, any sex, with Diabetes or Hypercholesterolemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In 2021-2022, Agence Sanitaire et Sociale Nouvelle Calédonie (ASSNC) is undertaking the "Baromètre Santé Adulte" for the third time. This study is carried out this year in collaboration with WHO and Institut Pasteur de Nouvelle Calédonie (IPNC). The main objective of this investigation is to describe the current levels of chronic disease risk factors in the adult population of New Caledonia aged from 18 to 64 years old. This study will also help to estimate prevalence of certain diseases (diabetes, hypercholesterolemia, renal failure), seroprevalence of arboviruses (dengue fever, Zika, chikungunya and Ross River) malaria as well as the seroprevalence of SARS-CoV-2. Repeated regularly, these surveys allow the ASS-NC to capitalize on population indicators, to compare them according to socio-demographic characteristics, to identify groups at risk, to provide changes in health behaviors and to strengthen analytical capacities in order to adapt the guidelines for public policies and prevention programs.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A seroprevalence study of SARS-CoV-2 and seasonal coronaviruses after the first SARS-CoV-2 circulation in New Caledonia, Pacific region.
Huet K, White M, Griffon AF, Bloch E, et al · · 2024 · cited 1× · PMID 38799796 · DOI 10.1016/j.ijregi.2024.100373
Investigating antibody cross-reactivity and transmission dynamics of alphaviruses and flaviviruses using a multiplex serological assay.
Yman V, Rosado J, Ochida N, Garcia L, et al · · 2026 · PMID 41986360 · DOI 10.1038/s41467-026-71451-7

Verify or expand the search:

Other trials of Blood sample

Trials testing the same drug.

NCT07226466 — Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer · not yet recruiting
NCT07313878 — Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Micros · NA · recruiting
NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
NCT07030205 — Resting-state Imaging and OSteoporosiS · NA · recruiting
NCT07295808 — Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN) · NA · recruiting

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05218304 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Agence Sanitaire et Sociale de Nouvelle Calédonie
Last refreshed: 1 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05218304.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing